Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 1572 clinical trials
Drug-Induced Liver Injury (DILN)Network Retrospective

The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic …

  • 14 Feb, 2021
  • 7 locations
CHIP/CCUS Natural History Protocol

Background Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a change in a person s DNA that can increase a person s risk of developing blood cancers or cardiovascular disease. CHIP occurs mostly occurs in older people. Clonal cytopenia of undetermined significance (CCUS) occurs when one or more blood cell types …

  • 19 Jul, 2021
  • 1 location
Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt

This is a hypothesis-generating pilot study. The intent is to model the impact of perioperative practices on the intestinal microbiome and possibly associate these conditions with the final microbiome status (e.g., number of resistance genes and diversity associated with perioperative practices and preoperative microbiome status). Participants will include individuals who …

  • 25 Jan, 2021
  • 2 locations
Investigation of Factors Affecting Cardiorespiratory Fitness in Individuals With Systemic Hypertension

The investigators aim to investigate the factors affecting cardiorespiratory fitness in individuals with systemic hypertension.

  • 24 Feb, 2021
  • 1 location
Registry for Patients With X-Linked Hypophosphatemia

This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH). The main objective of this XLH Registry is to collect data to characterise the treatment, progression and long-term outcomes of XLH in both adult and paediatric settings.

  • 22 Aug, 2021
  • 114 locations
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners

Through observation of patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) for up to 5 years, the study intends to collect data that allow achievement of the following objectives To determine medical characteristics of the disease and the disease process To determine physical and psychological burden on patients as well as economic …

  • 15 Feb, 2021
  • 1 location
Calcitriol Monotherapy for X-Linked Hypophosphatemia

Children and adults with XLH recruited will be treated with calcitriol alone (without phosphate supplementation) for one year, during which the calcitriol dose will be escalated during the first 3 months of therapy. The investigators hypothesize that treatment of adults and children with XLH alone will improve serum phosphate levels …

  • 26 Jan, 2021
Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Paediatric Patients from Birth to Less than 1 Year of Age with X-linked Hypophosphatemia (XLH)

  • 17 Aug, 2021
  • 6 locations
Characterising Pain QoL Body Composition Arterial Stiffness Muscles and Bones in Adult Persons With XLH and Healthy Controls

Hereditary hypophosphatemia (XLH) is a rare, inherited disease. Loss-of-function mutation in the phosphate regulating gene with homologies to endopeptidases on the X-chromosome (PHEX) results in excess fibroblast growth factor 23 (FGF23) production and manifests as rickets in children and osteomalacia in adults. This study aims to characterize and measure pain, …

  • 27 Jan, 2021
  • 1 location
Examining the Effect of Burosumab on Muscle Function

Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness particularly after exertion, in addition to their skeletal complaints. In previous trials using KRN23 (same drug as burosumab/Crysvita), patients report these symptoms improve. The investigators wish to test this hypothesis directly by measuring muscle energy when patients begin …

  • 29 Jan, 2021
  • 1 location